Schedule A LOCATION OF DEBTORS ACCOUNTS AND RECORDS

EX-10.9 10 dex109.htm SCHEDULES TO THE SECURITY PURCHASE AGREEMENT Schedules to the Security Purchase Agreement

EXHIBIT 10.9

Schedule A

LOCATION OF DEBTORS ACCOUNTS AND RECORDS

Accentia Biopharmaceuticals, Inc.

324 South Hyde Park Avenue, Suite 350

Tampa, Florida 33606

Accentia Specialty Pharmacy, Inc.

324 South Hyde Park Avenue, Suite 350

Tampa, Florida 33606

AccentRx, Inc.

324 South Hyde Park Avenue, Suite 350

Tampa, Florida 33606

Schedule B

PERMITTED LIENS

None.

Schedule C

FILINGS OR RECORDATIONS IN GOVERNMENTAL OR REGULATORY AUTHORITY,

AGENCY, OR RECORDING OFFICE

At closing, all security interests in the Collateral, except those granted hereby to the Secured Parties under this Agreement, will be released.

Schedule D

DEBTORS’ STATE OF ORGANIZATION

 

Company Name

  

Date of Incorporation

  

State of Incorporation

Accentia Biopharmaceuticals, Inc.   March 26, 2002   Florida
    P02000033509
Accentia Specialty Pharmacy, Inc.   April 27, 2004   Florida
    P04000068477
AccentRX, Inc.   March 26, 2002   Florida
    P02000033522

Schedule E

DEBTORS’ NAMES

 

(i) Debtor Name: Accentia Biopharmaceuticals, Inc.

 

(ii) Does not have any trade names

 

(iii) Accentia, Inc. changed on May 11, 2005

 

(iv) Accentia Specialty Pharmacy – merged on April 27, 2004

 

  TEAMM Pharmaceuticals, Inc. – merged on April 30, 2003

 

  Biovest International, Inc. – investment, majority shareholder on June 16, 2003

 

(i) Debtor Name: Accentia Specialty Pharmacy, Inc.

 

(ii) Does not have any trade names

 

(iii) Has not used any name other than that stated for the preceding five years

 

(iv) Was acquired and merged into Accentia Biopharmaceuticals, Inc. on April 27, 2004

 

(i) Debtor Name: AccentRx, Inc.

 

(ii) Does not have any trade names

 

(iii) Has not used any name other than that stated for the preceding five years

 

(iv) Was not acquired or merged into any Debtor within the past five years

Schedule F

Intellectual Property Related to SinuNase and Revimmune; including License Rights (In-Licensed)

 

Atty

Docket #

  

Country

  

Status

  

Application #

  

Pub. #

  

Filing

Date

  

Priority

  

Title

  

Owner/Assignee

  

Inventors

  

Patent
#

  

Issue
Date

  

Assoc.
Tech.

ACZ-014   US   PENDING   11/777,890     7/13/2007  

2/9/07 - 60/900,593

7/13/2006 - 60/830,528

   METHODS AND COMPOSITIONS FOR TREATING MUCOSAL INFLAMMATION   Accentia Biopharmaceuticals, Inc.   Francis E. O’Donnell, Jr.       SinuNase
ACZ-014PC   PCT   PENDING   PCT/US2007/016000   WO 2008/008494 (1/17/08)   7/13/2007  

2/9/07 - 60/900,593

7/13/2006 - 60/830,528

   METHODS AND COMPOSITIONS FOR TREATING MUCOSAL INFLAMMATION   Accentia Biopharmaceuticals, Inc.   Francis E. O’Donnell, Jr.       SinuNase
ACZ-016PC   PCT   PENDING   PCT/US2007/080333   WO 2008/063756 (5/29/2008)   10/3/2007  

1/19/07 - 60/881,270

10/3/06 - 60/849,028

   MUCOSALLY NON-IRRITATIVE AMPHOTERICIN B FORMULATIONS AND METHODS FOR TREATING NON-INVASIVE FUNGUS-INDUCED MUCOSITIS   Accentia, Biopharmaceuticals Inc.   Francis E. O’Donnell, Jr.; Donald Deroo       SinuNase
ACZ-024-1   US   PENDING   61/027,736     2/11/2008     MUCOSALLY NON-IRRITATIVE AMPHOTERICIN B LIQUID FORMULATIONS AND METHODS FOR TREATING NON-INVASIVE FUNGUS-INDUCED MUCOSITIS   Accentia Biopharmaceuticals, Inc.   Francis E. O’Donnell, Jr.; Donald Deroo       SinuNase
ACZ-026-1   US   PENDING   61/038,679     3/21/2008     DEVICES AND METHODS FOR DETERMINING THE EFFICACY OF A NON-SURGICAL INTERVENTION FOR THE TREATMENT OR PREVENTION OF CHRONIC RHINOSINUSITIS   Accentia Biopharmaceuticals, Inc.   Francis E. O’Donnell, Jr.; Angelos M. Stergiou; Susan Bonitz; Carlos Santos       SinuNase
ACZ-027-1   US   PENDING   61/041,866     4/2/2008     FORMULATIONS, DEVICES AND METHODS FOR TREATING NON-INVASIVE FUNGUS-INDUCED MUCOSITIS   Accentia Biopharmaceuticals, Inc.   Francis E. O’Donnell, Jr.; Angelos M. Stergiou       SinuNase

Atty

Docket #

  

Country

  

Status

  

Application #

  

Pub. #

  

Filing

Date

  

Priority

  

Title

  

Owner/Assignee

  

Inventors

  

Patent
#

  

Issue
Date

  

Assoc.
Tech.

JHV-060.25   PCT   PENDING   PCT/US2007/78521   WO 2008/034074 (3/20/08)   9/14/2007   9/15/06 - 60/844,830   USE OF HIGH DOSE CYCLOPHOSPHAMIDE IN COMBINATION WITH ANTI-IDIOTYPIC VACCINES IN ANTI-CANCER THERAPY   Johns Hopkins University and Accentia Biopharmaceuticals, Inc.   Robert A. Brodsky; Richard J. Jones; Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos       Revimmune
JHV-059.25   PCT   PENDING   PCT/US2007/78518   WO 2008/034071 (3/20/08)   9/14/2007   9/15/06 - 60/844,829   METHOD OF IDENTIFYING PATIENTS SUITABLE FOR HIGH-DOSE CYCLOPHOSPHAMIDE TREATMENT   Johns Hopkins University and Accentia Biopharmaceuticals, Inc.   Robert A. Brodsky; Richard J. Jones; Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos       Revimmune
JHV-062.25   PCT   PENDING   PCT/US2007/81614   Anticipated Pub. Date: 5/8/08   10/17/2007   11/3/06 - 60/856,698   USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS IN COMBINATION WITH MONOCLONAL ANTIBODIES FOR TREATING IMMUNE DISORDERS   Johns Hopkins University and Accentia Biopharmaceuticals, Inc.   Robert A. Brodsky; Richard J. Jones; Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos       Revimmune
RIZ-006-1   US   PENDING   60/989,628     11/21/2007     METHODS OF PROVIDING A SYSTEM OF CARE FOR A HIGH-DOSE REGIMEN OF AN OXAZAPHOSPHORINE DRUG   Accentia Biopharmaceuticals, Inc.   Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos       Revimmune
ACZ-025-1   US   PENDING   61/038,033     3/19/2008     METHOD OF IDENTIFYING PATIENTS SUITABLE FOR HIGH-DOSE OXAZAPHOSPHORINE TREATMENT   Accentia Biopharmaceuticals, Inc.   Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos       Revimmune

 

Atty

Docket #

  

Country

  

Status

  

Application #

  

Pub. #

  

Filing
Date

  

Priority

  

Title

  

Owner/Assignee

  

Inventors

  

Patent
#

  

Issue
Date

  

Assoc.
Tech.

RIZ-007-1   US   PENDING   61/022,774     1/22/2008     USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS FOR TREATMENT AND PREVENTION OF TRANSPLANT REJECTION   Johns Hopkins University and Accentia Biopharmaceuticals, Inc.   Robert Brodsky; Richard J. Jones; Susan Bonitz; Francis E. O’Donnell, Jr.; Carlos Santos       Revimmune

SinuNase Agreements

1 - License Agreement between Mayo Foundation and Accentia Biopharmaceuticals, Inc., effective February 10, 2004, amended Dec. 23, 2004, Aug. 22, 2006, April 16, 2007, August 30, 2007, and pending

2 - Marketing Agreement between TEAMM Pharmaceuticals, Inc. and IMMCO Diagnostics, Inc., effective June 30, 2005

3 - Option Agreement between Mayo Foundation and Accentia Biopharmaceuticals, Inc., effective December 6, 2005, amended July 20, 2006, May 9, 2007, and pending

4 - Non-exclusive Sublicense between Accentia Specialty Pharmacy, Inc. and JCB Laboratories, LLC, effective January 1, 2007

5 - Non-exclusive Sublicense between Accentia Specialty Pharmacy, Inc. and AnazaoHealth Corporation, effective February 1, 2007

Revimmune Agreements

1 - Sublicense Agreement between Revimmune, LLC and Accentia Biopharmaceuticals, Inc., effective February 27, 2007, amended April 18, 2008 and June 16, 2008

2 - License Agreement between Johns Hopkins University and Revimmune, LLC, effective February 20, 2006

3 - License Agreement between Accentia Biopharmaceuticals, Inc. and Biovest International, Inc., pending

Schedule F

Intellectual Property Related to SinuNase and Revimmune; including License Rights (In-Licensed)

(Continued)

SinuNase

Trademarks

 

Atty Docket #

   

Country

   

Trademark

   

Status

   

Owner

   

Application #

   

Filing Date

   

Reg. #

   

Reg. Date

ACZ-0705    US    SINUNASE    FILED    Accentia Biopharmaceuticals, Inc.    78/540118    12/30/2004      
ACZ-0705AU    Australia    SINUNASE    FILED    Accentia Biopharmaceuticals, Inc.    1092277    12/21/2005      
ACZ-0705CA    Canada    SINUNASE    FILED    Accentia Biopharmaceuticals, Inc.    1242790    1/6/2005      
ACZ-0705CTM    Europe    SINUNASE    Registered    Accentia Biopharmaceuticals, Inc.    4236147    1/10/2005    4236147   
ACZ-0705JP    Japan    SINUNASE    FILED    Accentia Biopharmaceuticals, Inc.    2005-120651    12/22/2005    4977873   
ACZ-0708    US    SINUTEST    Published    Accentia Biopharmaceuticals, Inc.    78/664701    7/6/2005      
ACZ-0708AU    Australia    SINUTEST    FILED    Accentia Biopharmaceuticals, Inc.    1092278    12/21/2005    1092278   
ACZ-0708CA    Canada    SINUTEST    Pending    Accentia Biopharmaceuticals, Inc.    1284178    12/21/2005      
ACZ-0708CTM    Europe    SINUTEST    Published    Accentia Biopharmaceuticals, Inc.    4805248    12/23/2005      

SinuNase

Trademarks

 

Atty Docket #

   

Country

   

Trademark

   

Status

   

Owner

   

Application #

   

Filing Date

   

Reg. #

   

Reg. Date

ACZ-0708JP    Japan    SINUTEST    FILED   

Accentia Biopharmaceuticals,

Inc.

    2005-120653    12/22/2005    5034132   
ACZ-0709    US    SINULES    Published   

Accentia Biopharmaceuticals,

Inc.

    78/678158    7/26/2005      
ACZ-0710    US    FUNGINASE    Published   

Accentia Biopharmaceuticals,

Inc.

    78/830090    3/6/2006      
ACZ-0712    US    SINUSEPTIC    Published   

Accentia Biopharmaceuticals,

Inc.

    78/936216    7/24/2006      
ACZ-0714    US    MUCONASE    Published   

Accentia Biopharmaceuticals,

Inc.

    77/36732    12/20/2007      

Schedule pp

FEDERAL ASSIGNMENT OF CLAIMS ACT

 

Accentia Biopharmaceuticals, Inc.    NONE
Accentia Specialty Pharmacy, Inc.    NONE
AccentRx, Inc.    NONE